


JAN. 31. 2005 10:18AM

OBLON SPIVAK :

NO. 564 P. 1



FOR IFW ✓

FACSIMILE

PLEASE CALL US AT (703) 413-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIBLE

ATTORNEYS AT LAW

FOURTH FLOOR
1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202
USA

(703) 413-3000
(703) 413-2220 FACSIMILE

OBLONPAT@OBLON.COM

PATENT, TRADEMARK AND COPYRIGHT LAW
AND RELATED FEDERAL AND ITC LITIGATION

WWW.OBLON.COM

TO		Examiner Saidha	January 11, 2005 1/11/0
NAME		PTO	DATE
COMPANY/FIRM		571-273-0940	FAX #
NUMBER OF PAGES INCLUDING COVER: 4		CONFIRM FAX: <input type="checkbox"/> YES <input type="checkbox"/> NO	
FROM		Thomas M. Cunningham	220738US
NAME		703-412-6563	OUR REFERENCE
DIRECT PHONE #		10/088,092 ✓	YOUR REFERENCE

MESSAGE

Dear Examiner Saidha:

Thank you for the signed and initialed copy of the IDS filed 3/21/02. We are still missing a signed copy of the IDS filed 3/10/2003 which lists (6) documents. Please find attached a copy of this IDS for your convenience.

Would you sign and return fax this 1449 to us?

Please call me if you have any questions.

With best regards,

Thomas M. Cunningham

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

OSMM&N File No. 220738US0PCT

Dept.: NFO/smp FF

Serial No. 10/088,092

Due Date: 03/10/03

In the matter of the Application of: Jun ISHIZAKI et al.

For: A GENE ENCODING NOVEL HUMAN SECRETORY TYPE
PHOSPHOLIPASE A2

The following has been received in the U.S. Patent Office on the date stamped hereon:

☐ Check for☐ Assignment: 2 pages/PTO 1595☒ Information Disclosure Statement☒ Cited References (6)☒ Dep. Acct. Order Form☒ Statement of Relevancy☒ PTO-1449☒ European Search Report☐ Cited Pending
Applications☐ IDS/Related/List of Related Cases☐☐**Rec'd PCT/PTO 10 MAR 2003**

Received: _____

Docket No. 220738US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Jun ISHIZAKI, et al

SERIAL NO: 10/088,092

FILED: March 21, 2002

FOR: A GENE ENCODING NOVEL HUMAN SECRETORY TYPE PHOSPHOLIPASE A2

GAU:

EXAMINER:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 03/02)

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

SHEET 1 OF 1

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 220738US0PCT		SERIAL NO. 10/088,092	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Jun ISHIZAKI, et al.			
				FILING DATE March 21, 2002		GROUP 1652	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO						
	AP						
	AQ						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
J/8	AR	Jun ISHIZAKI et al.: "Cloning and characterization of novel mouse and human secretory phospholipase A2s" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 35, pages 24973-24979 08/27/99					
	AS	Y. YOKOTA et al.: "Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1438, no. 2, pages 213-222 05/18/99					
	AT	E.D. MIHELICH et al.: "Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A2 inhibitors, SPI" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1441, no. 2-3, pages 223-228 11/23/99					
	AU	E.A. DENNIS: "The growing phospholipase A2 superfamily of signal transduction enzymes" TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 22, no. 1, pages 1-2 1997					
	AV	G. LAMBEAU et al.: "Receptors for a growing family of secreted phospholipase A2" TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 20, no. 4, pages 162-170 04/99					
J/8	AW	Noriko SUZUKI et al.: "Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A2s" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 8, pages 5785-5793 02/25/00					<input type="checkbox"/> Additional References sheet(s) attached
Examiner T. Saidha				Date Considered 1/31/05			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

A copy of this DS was handed
over to Tom. Cunningham, Applicants' Rep. on 1/31/05.



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	JUN ISHIZAKI ET AL: "Cloning and characterization of novel mouse and human secretory phospholipase A2s" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 35, 27 August 1999 (1999-08-27), pages 24973-24979, XP002130207 * the whole document *	1-16	C12N9/20 C12N15/55 C12P21/02 C12P21/08 C07K16/40
X,D	YOKOTA Y ET AL: "Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1438, no. 2, 18 May 1999 (1999-05-18), pages 213-222, XP004277148 * figure 1 *	17,18	
P,X	MIHELICH E D ET AL: "Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A2 inhibitors, SPI" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1441, no. 2-3, 23 November 1999 (1999-11-23), pages 223-228, XP004277276 * figure 1 *	17,18	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C12N
A	DENNIS E A: "The growing phospholipase A2 superfamily of signal transduction enzymes" TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 22, no. 1, 1997, pages 1-2, XP004016851 ISSN: 0968-0004 * the whole document *	1-18	
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search MUNICH		Date of completion of the search 27 January 2003	Examiner Weikl, M
CATEGORY OF CITED DOCUMENTS			
X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document		T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons ----- &: member of the same patent family, corresponding document	



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	LAMBEAU G ET AL: "Receptors for a growing family of secreted phospholipases A2" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 20, no. 4, April 1999 (1999-04), pages 162-170, XP004172557 ISSN: 0165-6147 * the whole document *	1-18	
P,X	SUZUKI NORIKO ET AL: "Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A2s." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 8, 25 February 2000 (2000-02-25), pages 5785-5793, XP002228755 ISSN: 0021-9258 * the whole document *	1-16	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search MUNICH		Date of completion of the search 27 January 2003	Examiner Weigl, M
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	